Evidence map›Paper›PMID 39530049›Full record

ArticleIn silico pharmacology2024

Hesperidin's role in the treatment of lung cancer:

Swati Arora, Sumit Sheoran, Bhuvanesh Baniya, Naidu Subbarao, Himanshu Singh, Dhamodharan Prabhu, Neeraj Kumar, Smita C Pawar, Sugunakar Vuree

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In silico pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Hesperetin induces apoptosis in lung squamous carcinoma cells via GInternational journal of molecular medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Swati AroraSchool of Bioengineering and Biosciences, Lovely Professional University, Jalandhar, Punjab India.
Sumit SheoranSchool of Bioengineering and Biosciences, Lovely Professional University, Jalandhar, Punjab India.
Bhuvanesh BaniyaDepartment of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur, Rajasthan India.
Naidu SubbaraoSchool of Computational and Integrative Sciences, JNU, New Delhi, India.
Himanshu SinghSchool of Bioengineering and Biosciences, Lovely Professional University, Jalandhar, Punjab India.
Dhamodharan PrabhuCentre for Drug Discovery, Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore, 641021 India.
Neeraj KumarDepartment of Pharmaceutical Chemistry, Bhupal Noble's College of Pharmacy Udaipur, Rajasthan, 313001 India.
Smita C PawarDepartment of Genetics and Biotechnology, Osmania University, Hyderabad, India.
Sugunakar VureeDepartment of Research and Development, Indo-American Cancer Research Foundation, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana 500034 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung Cancer remains a significant health concern, necessitating the exploration of novel therapeutic avenues due to the limited efficacy and adverse effects of current treatments. In this study, we utilized a thorough Graphical Abstract:

Indexed as

EGFRHesperidinIn-silicoIn-vitroLung cancer

Identifiers

PMID39530049
PMCPMC11550299

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.